The Latin American Pharmaceutical Market will reach $87.29bn in 2018 predicts new visiongain report

LONDON - Dec. 17, 2015 - PRLog -- The Latin American pharmaceutical market will reach $87.29bn in 2018 predicts new visiongain report

A new report by visiongain predicts that the Latin American pharmaceutical market will reach $87.29bn in 2018. This forecast and others appear in Latin American Pharmaceutical Market Outlook 2015-2025, published in September 2015. Visiongain is a business information provider based in London, UK.

The pharmaceutical market is at different stages of development across Latin America. In the case of both developed and developing health care systems there is room for significant growth, but also many challenges. This report focuses on understanding the unique opportunities and challenges faced in Latin America, as well as within different countries and regions, such as increasing rates of diabetes and the effect of an ageing population. The different submarkets of the pharmaceutical market are explored in each country, giving unprecedented insight. The economic situation in Latin America and globally is important to the local pharmaceutical industry and its effects are explored in depth. Through a bottom-up approach, this report provides invaluable market knowledge and predictions.

Jack Evans, a pharmaceutical and medical devices industry analyst in visiongain, said: “The Latin American pharmaceutical market will continue to grow at a much higher rate than other, more mature markets for the next ten years. The reasons behind this growth will shift from expanding coverage to increasing incidence of diseases as the nations of Latin America develop economically. Governments across the region are looking to increase access to health care and an ageing population coupled with rises in the incidence of chronic diseases are driving demand.

Competition is high from both foreign and domestic companies, and national regulations can make investment difficult. Nevertheless, success in the Latin American pharmaceutical market is crucial for pharmaceutical companies seeking to maintain growth rates as developed markets stagnate.”

Visiongain’s report provides revenue forecasts to 2025 for the Latin American pharmaceutical market and its leading national markets:

·        Brazil,

·        Mexico,

·        Venezuela,

·        Argentina,

·        Colombia and

·        Chile.

The Rest of Latin America is also assessed as a grouped category with revenue forecasts to 2025. The report also provides forecasts for the following product class for the Latin American market and each of the leading national markets:

·        Generic drugs,

·        Over-the-counter products,

·        Biosimilars and

·        Originator drugs.

The report discusses selected leading companies hold significant shares of the market. These companies include Sanofi, EMS, Novartis, Pfizer and Bayer. Visiongain’s report also discusses key economic points, commercial news, and analysis of strengths, weaknesses, opportunities and threats.

Latin American Pharmaceutical Market Outlook 2015-2025 adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com

Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100.
About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.